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Venous malformations (VMs), lymphatic malformations (LMs), cutaneous capillary malformations, together with their derived combined lesions, are currently consid-ered low-flow vascular malformations (LFMs). They are congenital, hence already 
present at birth, and grow along with the growth of the individual. They can present focal-
ly, multifocally or diffusely, with possible infiltration of superficial and deep structures (1). 
The International Society for the Study of Vascular Anomalies (ISSVA) has published a clas-
sification system, based on biological features, which is a landmark for proper distinction 
between the various types of anomalies, and is currently the most widely used (2).
Dedicated categorizations for LMs have also been proposed, like the anatomy-based clas-
sification system for head and neck LMs by de Serres et al. (3), which made a grading/stag-
ing system possible, and the radiology-based distinction between macrocystic, microcystic, 
and mixed LMs, which has therapeutic implications (4).
It has been reported that unilateral lesions below the hyoid bone tend to be macrocys-
tic and to have a better response to nonsurgical treatment, while lesions located above 
the hyoid tend to be frequently microcystic or mixed and to have worse results in terms of 
treatment efficacy (5, 6).
The diagnosis in the postnatal period is usually made clinically. Doppler ultrasonography 
(US) and magnetic resonance imaging (MRI) with and without contrast are required to con-
PURPOSE 
We aimed to evaluate the safety and effectiveness of percutaneous sclerotherapy using gelified 
ethanol in patients with low-flow malformations (LFMs).
METHODS
A retrospective study was performed, analyzing treatment and outcome data of 6 patients that 
presented with 7 LFMs (3 lymphatic and 3 venous). Median diameter of LFMs was 6 cm (inter-
quartile range [IQR], 4.5–8.5 cm). Data regarding pain, functional and/or cosmetic issues were 
assessed. Diagnosis was performed clinically and confirmed by Doppler ultrasound, while ex-
tension of disease was assessed by magnetic resonance imaging (MRI). Percutaneous puncture 
was performed with 23G needle directly or with ultrasound guidance. All the LFMs were treated 
with gelified ethanol injection. The median volume injected per treatment session was 4.4 mL. 
RESULTS
Technical and clinical success were obtained in all cases. No recurrences were recorded during a 
median follow up of 17 months (IQR, 12–19 months). Among the 6 patients, 5 had complete re-
lief (83%) and one showed improvement of symptoms. The median VAS score was 7 (IQR, 6–7.5) 
before and 0 (IQR, 0–0) after treatment. All patients had functional and esthetic improvement 
(100%). Four patients (66.7%) revealed very good acceptance and two patients (33.3%) good 
acceptance. No major complications or systemic side effects were observed. 
CONCLUSION
Gelified ethanol percutaneous sclerotherapy was easy to handle, well-tolerated, safe and effec-
tive in the short-term follow-up. Longer follow-up of efficacy is mandatory for further conclu-
sions.
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firm the diagnosis and to better define each 
malformation (7).
In general, the absence of the flow-void 
effect differentiates LFMs from high-flow 
lesions. Macrocystic LMs, unlike VMs, have 
large vascular chambers with no contrast 
enhancing properties, and do not contain 
phleboliths. The differential diagnosis be-
tween microcystic LMs and VMs can be 
harder, but VMs have a detectable flow in 
the majority of cases, and their appearance 
changes with position (6).
Although LMs can be found in any ana-
tomic region, their most frequent localiza-
tions are in areas with a naturally high con-
tent of lymphatic tissue, like head and neck 
(45%–52%), axillae, mediastinum, groin, 
and retroperitoneum (7, 8). VMs can man-
ifest at any location of the body as a solid 
soft tissue mass consisting of multiple en-
larged venous channels and lakes (9). The 
clinical presentations of both VMs and LMs 
are extremely variable, depending on the 
location and the dimension of the lesion.
Treatment is currently indicated in cases 
of pain, swelling of tissues, invasion of func-
tionally and/or cosmetically relevant struc-
tures, as well as in cases of thromboembolic 
complications and sepsis. Surgical and non-
surgical treatments have been described. 
In many cases percutaneous sclerother-
apy has been reported as first-line thera-
py. Various sclerosing agents have been 
reported; ethanol, bleomycin, doxycycline, 
and picibanil (OK-432) are the most com-
monly described, but also the use of acetic 
acid and fibrin glue can be found in liter-
ature (6, 10). Some sclerosing agents, in 
particular absolute ethanol, are at risk of 
adverse events related to the harmful effect 
that the agent can have on healthy tissues 
surrounding the malformations. Compli-
cations such as nerve damage, skin break-
down and swelling have been described. 
The latter may be managed with intubation 
and intensive care unit observation, but 
sometimes tracheotomy is required.
An ideal sclerosing product should be 
characterized by a high efficacy on the tar-
get malformation, like absolute alcohol, but 
should also have a low diffusibility to avoid 
harmful effects on the healthy surrounding 
tissues.
Recently, a new sclerosing agent has been 
developed. It was obtained by mixing pure 
alcohol with an absorbable gelling, cellulose 
derivative that is hydrophilic, non-toxic, and 
soluble in alcohol. This agent has already 
been used for embolization in the form of 
microspheres or associated with cisplatin, 
bismuth trioxide (11), and tantalum (12).
The benefits of this gelified ethanol, 
when compared with pure alcohol, seem 
to include better efficacy and, at the same 
time, a lower risk of damage to any sur-
rounding healthy tissue, due to the fact that 
smaller quantities of ethanol are used, in-
creasing safety (13).
We are presenting our preliminary re-
sults in terms of efficacy and safety in pa-
tients with LFMs treated with percutaneous 
sclerotherapy using gelified ethanol.
Methods
Patients
A retrospective study was performed af-
ter approval of our Internal Review Board. 
Between January 2017 and November 2017, 
6 patients presented to the Department of 
Maxillo-Facial Surgery of our Institution with 
7 LFMs that were treated percutaneously 
with injection of gelified ethanol. Sex and 
age of patients, together with type and size 
of lesions, were assessed (Table 1). Lesions 
were classified, according to their type, using 
the ISSVA classification (2). The diagnosis was 
made on the basis of clinical and ultrasound 
examination. The extension of the malfor-
mation and its anatomical relations with the 
surrounding tissues and organs were stud-
ied with MRI. Each case was discussed by 
a multidisciplinary team with involvement 
of maxillo-facial surgeons, plastic surgeons, 
radiologists and interventional radiologists. 
Indications, benefits and risks of each proce-
dure were explained and discussed with the 
patients, and informed consent was obtained 
before treatment. This study was conducted 
in accordance with the ethical standards of 
the institutional and/or national research 
committee and with the 1964 Helsinki decla-
ration and its later amendments or compara-
ble ethical standards.
Procedure
Coagulation blood tests resulted with-
in the reference values in all patients (14). 
Each patient was given a first-generation 
cephalosporin (cefazolin 2 g b.i.d., Pfizer 
Srl) at the beginning of the procedure as 
prophylaxis. Anesthesiologic specialized 
support was not needed for two patients, in 
whom only local anesthesia was performed. 
An anesthesiologist was present in the oth-
er cases. Moderate sedation was achieved 
in 3 patients through intravenous injection 
of propofol, fentanyl, and midazolam. Gen-
eral anesthesia was required for one patient 
in relation to the proximity with airways. Vi-
tal parameters, oxygen saturation, and elec-
trocardiographic tracing were continuously 
monitored.
A 23G butterfly needle (Terumo) was po-
sitioned under US-guidance (Arietta V70, 
Hitachi Aloka Medical) in two cases. In the 
remaining cases, direct puncture of the 
malformation was performed and the cor-
rect position of the needle was verified with 
US. In all cases a lymph or blood back-flow 
was obtained. In LMs, complete aspiration 
of lymph was performed before injecting 
the gelified ethanol (Sclerogel, Ab Medi-
ca). In VMs, contrast agent was injected to 
define the anatomy of the malformation 
and visualize potential large draining veins, 
which should not be sclerosed.
More than one puncture was necessary 
in all cases because all malformations con-
sisted of several chambers that were rarely 
communicating. In two patients, Sclerogel 
was used to embolize the deepest compo-
nents, closer to vessels or trachea.
The amount of sclerosing agent used was 
equal to the volume of lymph aspirated in 
Main points
• Percutaneous sclerotherapy is currently the 
main therapeutic alternative to surgery in 
the treatment of low-flow vascular malfor-
mations, like venous and lymphatic malfor-
mations. It can be used alone, if surgery is 
contraindicated, or as a bridge to resection.
• Sclerogel consists of ethanol, confined 
by a gelous network, and combined with 
water-insoluble cellulose derivative. This 
composition has several advantages when 
compared to pure liquid alcohol, including 
longer contact to the vessel wall, more rapid 
dehydration of the vessel wall, lower content 
of ethanol needed per treatment, and better 
control of allocation.
• To date, efficacy of gelified ethanol in terms 
of therapeutic results, has been reported 
to be at least as good as absolute ethanol. 
However, there is still no evidence describing 
which agent is better in terms of outcome, 
time of action, and the number of compli-
cations. In this study, we report our prelimi-
nary experience in the treatment of venous 
and lymphatic malformations with Sclerogel. 
We achieved technical and clinical success 
in all patients, with good results in terms of 
functional and cosmetic outcomes and the 
overall satisfaction of patients. No major 
complications or recurrence were recorded. 
A longer follow-up and a higher number of 
patients are mandatory.
LMs and to the volume of contrast media in-
jected to opacify the malformation in VMs; 
all volumes were recorded (Fig. 1).
This procedure was repeated over time 
for every patient until the achievement of 
a clinically and subjectively satisfying result.
Outcomes
Technical success was defined as posi-
tioning the needle into the different com-
partments of the target lesions, as planned 
before treatment. Clinical success was de-
fined as the improvement or disappearance 
of the symptoms. In particular, pain, func-
tional impairment, cosmetic impairment 
were recorded before and 12 months after 
treatment. Overall patient satisfaction after 
treatment was also recorded.
Before and after treatment pain was 
classified by patients using the visual ana-
logue scale (VAS), ranging from 1 to 10. For 
the evaluation of the other symptoms and 
aspects, the scoring method described by 
Dompmartin et al. (13) was adopted and 
modified, as shown in Table 2. Functional 
impairment, esthetic prejudice and overall 
patient satisfaction were all graded from 0 
to 2, and results were reported for each pa-
tient (Table 1) (13). 
Complications were classified according 
to Common Terminology Criteria for Ad-
verse Events (15, 16). Safety was evaluated 
on the basis of the complications record-
ed. These were classified as “immediate” if 
occurring within 24 hours after procedure, 
“peri-procedural” if occurring within 30 
days, and “delayed” if occurring more than 
30 days after procedure (16). Major compli-
cations were defined as events that, if un-
treated, could be judged life threatening, or 
that could have led to significant morbidity 
or disability, or could have caused readmis-
sion to the hospital or prolonged hospital 
stay (16). This group includes systemic side 
effects like hemolysis, renal or cardiovas-
cular failure. Minor complications included 
local side effects: edema, epidermolysis, 
hematoma, abscess, necrosis of the skin, 
paresthesia, and nerve palsy. 
Results
Table 1 reports sex and age of the pa-
tients, size and localization of the malfor-
mations, treatment history including the 
quantity of gelified ethanol used, and an-
esthesia type. A total of 7 malformations 
were treated in 6 patients (median age, 
35.5 years; interquartile range [IQR], 31–38 
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years), with one patient having two differ-
ent malformations with different symptom-
atology and esthetic issues.
Median diameter of LFMs was 6 cm (IQR, 
4.5–8.5 cm). Technical and clinical success 
were obtained in all cases. No recurrenc-
es were registered during the available 
follow-up (median 17 months; IQR, 12–19 
months); in one patient a residual portion 
of a malformation remained stable during 
the available follow-up (18 months) (Fig. 
2). 
Of the 6 patients, 5 experienced com-
plete relief of pain (83%) and one had 
pain improvement, with a residual pain of 
mild intensity that did not require therapy. 
The median VAS score of pain was 7 (IQR, 
6–7.5) before and 0 (IQR, 0–0) after treat-
ment. 
All patients had functional improve-
ment (100%). All patients (100%) had es-
thetic improvement. In terms of procedure 
tolerance, 4 patients (66.7%) showed very 
good acceptance and 2 patients (33.3%) 
good acceptance. Four patients who had 
been previously sclerosed with other scle-
rosing agents, noted less postprocedural 
swelling.
The median injected volume of gelified 
ethanol was 4.4 mL per treatment session. 
Three patients experienced post-sclero-
therapy local edema (Table 1), but none 
required special medications; patient 3 
was precautionarily intubated. No systemic 
ethanol contaminations were detected. No 
major complications neither systemic side 
effects, such as hemoglobinuria, hemolysis, 
renal failure, myocarditis, or collapse, were 
observed.
No particular pre-medications were used; 
when necessary, oral analgesia with parac-
etamol was prescribed to reduce pain sec-
ondary to the inflammatory reaction. The 
patient that underwent the procedure un-
der general anesthesia was followed in the 
intensive care unit for 24 hours. 
The data resulted insufficient for any sta-
tistical analysis.
Discussion
Surgical resection is the therapy of choice 
for LFM, but their frequent infiltrating na-
ture has been associated with high rates of 
relapse and complications such as lymphat-
ic effusions, infections, and local nervous 
lesions, so alternative treatments have also 
been looked for (17,1).
Percutaneous sclerotherapy is current-
ly the main therapeutic alternative, either 
alone in cases where surgery is not possible, 
or as a bridge to surgical resection.
Several agents have been used for per-
cutaneous treatment of vascular malfor-
mations such as Ethibloc, OK432, polydo-
canol, sodium tetradecyl sulphate (STS), 
doxycycline and bleomycin. In comparative 
analyses, no significant differences were de-
termined between these agents in terms of 
success rates.
The number of treatment sessions re-
quired to achieve an adequate result varies 
widely between cases, and more than 20 
sessions have been reported in some pa-
tients (1, 18, 19). 
This study reports preliminary results on 
the safety and effectiveness of percutane-
ous sclerotherapy of LFMs using gelified 
ethanol. Sclerogel consists of ethanol, with 
its strong sclerosing power, confined by a 
gelous network that limits its effusion into 
the surrounding healthy tissues. In this way 
the high efficacy of alcohol can be pre-
served, allowing a smaller volume to be 
used, and a better control can be achieved. 
One vial of Sclerogel contains gelified ethyl 
alcohol attached to a cellulose derivative. 
When injected, the gelified alcohol comes 
into contact with the vascular epithelium, 
for a time that is longer than the one ob-
served with pure liquid alcohol. The hydro-
philic property of ethanol causes dehydra-
tion of the vascular wall, which is enhanced 
by the presence of a macromolecule (wa-
ter-insoluble cellulose derivative) that in-
duces an osmotic effect. The cellulose de-
rivative in the presence of water allows the 
gelified alcohol of the emulsion to solidify 
and fill the vessel lumen. The ethanol re-
mains in situ, with a better control of its final 
allocation. The final result is the narrowing 
of the caliber of the vessels or of the (cystic) 
space in which Sclerogel is injected. 
In order to prolong the surface contact, 
Cabrera et al. (20) developed a foam made 
of polidocanol and carbon dioxide. The 
foam resulted more effective than other 
solutions for their original purpose, but the 
Table 2. Scoring system for the evaluation of sclerotherapy (13)
Evaluated features
Grades
2 1.5 1 0
Functional impairment Very good Significantly better Few improvements No change
Esthetic prejudice Very good Significantly better Few improvements No change
Patient satisfaction Very good Good Quite good Not satisfied
Figure 1. a, b. Percutaneous puncture of lymphatic malformation (a) and aspiration of lymphatic fluid (b).
a b
sclerosing efficacy of the detergent compo-
nents resulted lower than ethanol, with gas 
bubbles disappearing more rapidly than 
ethylcellulose.
Currently, efficacy of gelified ethanol in 
terms of therapeutic results, has been re-
ported to be at least as good as absolute 
ethanol (1, 21). However, there is still no 
evidence describing which agent is better 
in terms of outcome, time of action, and 
number of complications (13). Absolute 
pure liquid ethanol is generally used by 
experienced operators, but its use carries 
a risk of local and systemic complications, 
which have been reported between 7.5% 
and 28% (22). In our small series no major 
complications were noted; we attributed 
the high safety to the low amount of al-
cohol used, even though multiple injec-
tions were performed. Moreover, the rapid 
thickening of ethylcellulose in aqueous 
media makes its release and its cardiac 
toxicity less likely. The procedure resulted 
less painful and postprocedural swelling 
was less pronounced when compared 
with the use of other agents, as noted by 
the patients who had undergone previ-
ous sclerosing treatments. Ethylcellulose, 
which should give a palpable nodule in the 
site of injection, disappears spontaneously 
within 3–6 months.
All malformations were located in areas 
at high risk for local side effects, but in our 
series no side effects were noted except for 
swelling, which disappeared within a  few 
days, depending on the dimension of the 
treated malformation. We treated small 
lesions under local anesthesia, with all the 
related benefits. This is not possible when 
using absolute ethanol as the sclerosing 
agent. 
Some patients of our series present-
ed with residual disease or recurrence 
after sclerotherapy performed with oth-
er agents, or after surgery. Although the 
follow-up was not long enough, our pre-
liminary results in these patients are en-
couraging, because no residual disease 
nor recurrences were observed. Our clini-
cal success is in agreement with the data 
published by Teusch et al. (23): their mean 
follow up of 103 days is shorter than ours 
but more cases of LFMs, localized in differ-
ent areas (upper and lower extremities and 
face) were treated. Despite our positive 
preliminary results, we believe that a lon-
ger follow-up and larger series are surely 
needed. In the last 9 months Sclerogel was 
not available in our country so a slowdown 
in the collection of our data was inevitable.
Our study has limitations, such as its 
retrospective nature and the paucity of 
patients that has not allowed any statis-
tical analysis. Furthermore, the indication 
to treatment was given by experienced 
interventional radiologists and surgeons, 
but no strict and specific protocol was 
used. Clinical outcomes were based pri-
marily on subjective follow-up visits and 
less on postprocedural imaging; although 
imaging could be considered a good way 
to objectify results, we believe that rely-
ing on clinical assessments and subjective 
symptoms of patients is the best way to 
measure our treatments, since these are 
the true endpoints of the process.
In our opinion, sclerotherapy with Sclero-
gel can be indicated for areas at high risk 
for local side effects from the injection of 
absolute ethanol, such as perineural areas, 
the periocular region, the tongue, and ar-
eas close to airways (trachea). In these sites 
the lower diffusibility of gelified ethanol 
can in fact make a difference. An excessive 
amount of ethylcellulose can be harmful, so 
a careful injection is always recommended.
In conclusion, gelified ethanol may be 
considered easy to handle, well-tolerated, 
safe and effective according to a short-term 
follow-up. Further follow-up to evaluate 
long-term efficacy is mandatory.
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